What's breaking now, across thousands of outlets.
Analysts warn a disruption in Chinese sources of common antibiotics or blood thinners could leave American patients with no reliable alternative.
We haven't written up this one. The Diplomat has the full story — the link below goes straight to it.
More than six years after the pandemic arrived and ivermectin and hydroxychloroquine were first touted as COVID cures, the evidence shows more than ever that they don't work.
We deal with a seemingly endless conveyor belt of fad quack remedies (the proverbial game of whack-a-mole). We always have some new nonsense to deal with.
More than half of girls participating in the long-term U.S. Adolescent Brain Cognitive Development (ABCD) study developed painful periods (dysmenorrhea) by age 12 or 13, according to new research…
It offers a "safe way to target chemo resistant tumors," the study's author Ozgur Sahin told Newsweek.
Daniel Chojnowski, JHHP’s current CFO, will provide stability so that the Baltimore-area insurer can recruit full-time for its next chief executive, the company said.
Marlboro-maker Altria is seeking to force the FDA to overhaul a review process it says has blocked newer nicotine products from reaching the market.
